Intracerebral haemorrhage remains one of the most severe forms of stroke, with a major impact on mortality and long‑term disability. While the first hours are crucial to limiting haematoma expansion, much of the patient’s prognosis is determined in the days that follow.
It is within this often‑overlooked window that DARLENE takes place, developed as part of Work Package 3 of the RHU TIPITCH, and dedicated to a central challenge: modulating post‑haemorrhagic inflammation.
Perihaemorrhagic Oedema: A Key Determinant of Outcome
When an intracerebral haemorrhage occurs, the bleeding itself represents only the first stage of the cerebral injury. The sudden entry of blood into brain tissue destroys cells at the point of impact and triggers an intense inflammatory reaction.
This inflammatory response leads to the formation of perihaemorrhagic oedema, which progressively develops over the following days. This oedema exerts mass effect on the surrounding brain and worsens the initial injury. Its severity is closely linked to functional outcome:
the larger the oedema, the higher the risk of severe disability or death.
Physiologically, this inflammation results from the activation of resident brain immune cells — microglia — as well as the recruitment of inflammatory cells from the bloodstream. It is accompanied by breakdown of the blood–brain barrier, promoting accumulation of fluid and inflammatory cells in brain tissue.
An Ambivalent Process That Cannot Simply Be “Blocked”
While excessive inflammation is clearly harmful, it is not solely detrimental. It also plays an essential role in haematoma clearance and tissue repair.
This is the core complexity of the problem:
- blocking inflammation indiscriminately may hinder essential repair mechanisms;
- allowing it to unfold without intervention may lead to dangerous inflammatory escalation.
DARLENE is built on this nuanced understanding: the aim is not to suppress inflammation, but to modulate it — tempering its harmful components while preserving its beneficial effects.
An Unmet Therapeutic Need
In clinical practice, there is currently no validated medication specifically targeting inflammation after intracerebral haemorrhage. Corticosteroids have not shown benefit, and previous anti‑inflammatory trials have not demonstrated convincing clinical efficacy.
This lack of therapeutic options stands in stark contrast with the major role played by cerebral oedema in patient outcomes. DARLENE was born from this observation: a key determinant of prognosis remains therapeutically unaddressed.
DARLENE Within the TIPITCH Trajectory: An Integrated Approach
The DARLENE study fits perfectly within the global logic of TIPITCH, which targets the different stages of intracerebral haemorrhage:
- upstream, limiting vascular rupture and haematoma expansion;
- intermediate, reducing blood toxicity and promoting its evacuation;
- later, targeting inflammation and optimising repair mechanisms.
DARLENE corresponds to this third pillar. It complements early‑stage strategies by addressing a slower process that is equally decisive for long‑term functional outcome.
A Strong Biological Rationale: The NRF2 Pathway
The therapeutic choice evaluated in DARLENE is based on years of translational research, from experimental models to human observations. These studies highlight the central role of the NRF2 pathway in regulating post‑haemorrhagic inflammation.
NRF2 contributes both to:
- limiting excessive inflammatory mechanisms,
- supporting haematoma resolution and brain tissue repair.
The study evaluates the effect of an NRF2 agonist, Diroximel fumarate, using a drug‑repositioning strategy. Already authorised for other indications, it benefits from extensive safety data — a major asset for future potential clinical use.
A Clinical Study Designed Around Biological Time
DARLENE is a Phase 2B randomised, multicentre clinical trial, sponsored by CHU Lille and involving several French centres specialised in stroke care. Nearly 200 patients with spontaneous intracerebral haemorrhage will be enrolled.
One of the study’s most innovative aspects is the 21‑day treatment duration. This timeframe was defined to accompany the full course of inflammation, from oedema development to tissue repair.
The primary endpoint is the radiological measurement of cerebral oedema volume, supplemented by clinical criteria and close monitoring of treatment tolerance.
A Scientific and Human Innovation
Beyond its therapeutic approach, DARLENE stands out for its thoughtful organisation and follow‑up. The protocol benefited from the input of patients who had themselves experienced intracerebral haemorrhage, enabling adjustments to monitoring procedures and evaluation tools to reflect real‑world patient experience.
Furthermore, biological samples collected during the study will constitute a biobank, paving the way for future research on inflammation mechanisms and biomarkers of treatment response.
Long Term Prospects, Without Premature Promises
If DARLENE yields positive results, it will represent a major proof of concept, paving the way for a larger Phase 3 trial. The long‑term objective is clear:
to develop an accessible treatment that complements existing strategies and sustainably improves patient outcomes.
More broadly, DARLENE embodies the philosophy of TIPITCH:
challenging the perceived inevitability of intracerebral haemorrhage through rigorous, innovative, patient‑centred science.
